RepliCel Life Sciences (TSE:RP) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
RepliCel Life Sciences has announced the sale of its assets and licensing of patent rights to 1456390 B.C. Ltd, a company controlled by RepliCel’s CEO Andrew Schutte. The deal is seen as the best path forward for maximizing shareholder return and commercializing the assets. The agreement includes an 8% royalty on gross profits from the commercialized products, promising a potential value increase for shareholders.
For further insights into TSE:RP stock, check out TipRanks’ Stock Analysis page.